These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 27530615

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population.
    Kowalik A, Gąsior-Perczak D, Gromek M, Siołek M, Walczyk A, Pałyga I, Chłopek M, Kopczyński J, Mężyk R, Kowalska A, Góźdź S.
    Oncotarget; 2017 Aug 29; 8(35):58304-58308. PubMed ID: 28938557
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
    Hińcza K, Kowalik A, Kowalska A.
    Genes (Basel); 2019 Jun 26; 10(7):. PubMed ID: 31247975
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
    Zhu J, Wu K, Lin Z, Bai S, Wu J, Li P, Xue H, Du J, Shen B, Wang H, Liu Y.
    Mol Genet Genomic Med; 2019 Dec 26; 7(12):e1015. PubMed ID: 31642198
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
    Xing M.
    Clin Endocrinol (Oxf); 2005 Sep 26; 63(3):263-6. PubMed ID: 16117812
    [Abstract] [Full Text] [Related]

  • 35. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
    Marques IJ, Moura MM, Cabrera R, Pinto AE, Simões-Pereira J, Santos C, Menezes FD, Montezuma D, Henrique R, Rodrigues Teixeira M, Leite V, Cavaco BM.
    Clin Endocrinol (Oxf); 2017 Oct 26; 87(4):394-399. PubMed ID: 28502101
    [Abstract] [Full Text] [Related]

  • 36. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
    Ye F, Gao H, Xiao L, Zuo Z, Liu Y, Zhao Q, Chen H, Feng W, Fu B, Sun L, Jiang X, He D, Jiang H, Yang M, Li L, Chen F, Liu X, Li S, Li Z, Jiang Y, Cheng L, Bu H.
    Int J Cancer; 2019 Mar 15; 144(6):1321-1330. PubMed ID: 30132833
    [Abstract] [Full Text] [Related]

  • 37. Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer.
    Bauer AJ.
    Front Horm Res; 2013 Mar 15; 41():141-8. PubMed ID: 23652675
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Familial nonmedullary thyroid carcinoma.
    Mazeh H, Sippel RS.
    Thyroid; 2013 Sep 15; 23(9):1049-56. PubMed ID: 23734600
    [Abstract] [Full Text] [Related]

  • 40. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
    Tomaz RA, Sousa I, Silva JG, Santos C, Teixeira MR, Leite V, Cavaco BM.
    Clin Endocrinol (Oxf); 2012 Dec 15; 77(6):926-33. PubMed ID: 22882326
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.